In a subcutaneous (s.c.)mesothelioma patient-derived xenograft model (PDX #008), intravenous (i.v.)administration of 10 million NKG2D-CD3ζ- or NKG2D-engineered T cells on day 108 was completely ineffective (Figure 4A). This evidence concerns the gene KLRK1 and mesothelioma.